|
?:authorAffiliation
|
-
[\'Adimab, LLC, Lebanon, NH 03766, USA.\', \'Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.\', \'Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.\', \'Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.\', \'Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA 99164, USA.\', \'U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.\', \'The Geneva Foundation, Tacoma, WA 98402, USA.\', \'IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.\', \'Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.\', \'Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02139, USA.\', \'Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. rbaric@email.unc.edu lgralins@email.unc.edu laura.walker@adimab.com.\', \'Departments of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.\', \'Adimab, LLC, Lebanon, NH 03766, USA. rbaric@email.unc.edu lgralins@email.unc.edu laura.walker@adimab.com.\', \'Adagio Therapeutics, Inc., Waltham, MA 02451, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}